Global Epileptic Seizures Treatment Market
Global Epileptic Seizures Treatment Market

Epileptic Seizures Treatment Comprehensive Study by Type (Convulsive Status Epilepticus, Non-Convulsive Status Epilepticus), Therapeutic (Midazolam, Alprazolam, Diazepam, Phenytoin, Fosphenytoin, Others), Distribution Channel (Online, Offline), Route Of Administration (Oral, Rectal, Nasal, Parenteral), Seizures (Generalized Seizures, Whole Brain)

Epileptic Seizures Treatment Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Nov 2020 Edition 232 Pages 215 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Epileptic Seizures Treatment Market?

Epilepsy is a chronic disorder that causes unprovoked, recurrent seizures. A seizure is a sudden rush of electrical activity in the brain. and Epilepsy is categorized as a chronic disease of the brain and continues to affect millions of individuals worldwide. Although the prevalence of epilepsy is marginally higher in men compared to women, it affects individuals from all age groups. The prevalence of focal seizures is higher than that of generalized seizures in both, children as well as adults. The prevalence of epileptic seizures is higher in low to middle-income countries due to which, the demand for epileptic seizure treatment is high from developing regions. Some of the major factors responsible for the high prevalence of epileptic seizures in developing regions include acute symptomatic seizures, misdiagnosis, and lack of advanced medical infrastructure.

The market study is being classified by Type (Convulsive Status Epilepticus and Non-Convulsive Status Epilepticus) and major geographies with country level break-up.

Bausch Health Companies, Inc. (Canada), GlaxoSmithKline plc. (United Kingdom), UCB S.A. (Belgium), Pfizer, Inc. (United States), Apotex, Inc. (Canada), Alexza Pharmaceuticals, Inc. (United States), Neurelis, Inc. (United States) and Veriton Pharma (United Kingdom) are some of the key players profiled in the study.

The global Epileptic Seizures Treatment market is witnessing a rise in competitiveness among the players. In terms of market share, the major players are currently dominating. However, some of the companies are increasing the market presence by securing new contracts and tapping new markets. Research Analyst at AMA predicts that United Kingdom Players will contribute to the maximum growth of Global Epileptic Seizures Treatment market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Epileptic Seizures Treatment market by Type, Application and Region.

On the basis of geography, the market of Epileptic Seizures Treatment has been segmented into . Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Growing Focus On Providing Seizure-Free Life To Fuel Innovations
  • Growth in The Demand For Epileptic Seizures Treatment
  • Increase In Incidence Of Cardiovascular Diseases

Market Trend
  • Growing Focus On Providing Seizure-Free Life To Fuel Innovations

Restraints
  • Adverse Effect Of The Treatment

Opportunities
  • he Growth Of The Global Epileptic Seizures Treatment Market owing to the rise in Head Injuries, Brain Cancer, Infections, And Substance Abuse

Challenges
  • New Treatment Alternatives Have Gained Considerable Momentum


Market Leaders and some development strategies
In June 2020 Ucb Announced Their Acquisition With Engage Therapeutics For Usd 125 Million. Alprazolam, An Investigational Drug Being Developed By Engage Therapeutics For Active Epileptic Seizures. Currently, In Phase Ii Development, Staccato Alprazolam Is Being Developed As A Single-Use Epileptic Seizure Rescue Therapy. It Is A Combination Of The Staccato Delivery Technology With Alprazolam.



Key Target Audience
New Entrants/Investors, Analysts And Strategic Business Planners, Epileptic Seizures Treatment Manufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, And Distributors, Venture Capitalists And Private Equity Firms, Government Regulatory And Research Organizations and End-Use Industry

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Convulsive Status Epilepticus
  • Non-Convulsive Status Epilepticus
By Therapeutic
  • Midazolam
  • Alprazolam
  • Diazepam
  • Phenytoin
  • Fosphenytoin
  • Others

By Distribution Channel
  • Online
  • Offline

By Route Of Administration
  • Oral
  • Rectal
  • Nasal
  • Parenteral

By Seizures
  • Generalized Seizures
  • Whole Brain

By Regions
    • 1. Market Overview
      • 1.1. Introduction
      • 1.2. Scope/Objective of the Study
        • 1.2.1. Research Objective
    • 2. Executive Summary
      • 2.1. Introduction
    • 3. Market Dynamics
      • 3.1. Introduction
      • 3.2. Market Drivers
        • 3.2.1. Growing Focus On Providing Seizure-Free Life To Fuel Innovations
        • 3.2.2. Growth in The Demand For Epileptic Seizures Treatment
        • 3.2.3. Increase In Incidence Of Cardiovascular Diseases
      • 3.3. Market Challenges
        • 3.3.1. New Treatment Alternatives Have Gained Considerable Momentum
      • 3.4. Market Trends
        • 3.4.1. Growing Focus On Providing Seizure-Free Life To Fuel Innovations
    • 4. Market Factor Analysis
      • 4.1. Porters Five Forces
      • 4.2. Supply/Value Chain
      • 4.3. PESTEL analysis
      • 4.4. Market Entropy
      • 4.5. Patent/Trademark Analysis
    • 5. Global Epileptic Seizures Treatment, by Type, Therapeutic , Distribution Channel, Route Of Administration and Seizures (value, volume and price ) (2014-2019)
      • 5.1. Introduction
      • 5.2. Global Epileptic Seizures Treatment (Value)
        • 5.2.1. Global Epileptic Seizures Treatment by: Type (Value)
          • 5.2.1.1. Convulsive Status Epilepticus
          • 5.2.1.2. Non-Convulsive Status Epilepticus
        • 5.2.2. Global Epileptic Seizures Treatment by: Distribution Channel (Value)
          • 5.2.2.1. Online
          • 5.2.2.2. Offline
        • 5.2.3. Global Epileptic Seizures Treatment by: Route Of Administration (Value)
          • 5.2.3.1. Oral
          • 5.2.3.2. Rectal
          • 5.2.3.3. Nasal
          • 5.2.3.4. Parenteral
        • 5.2.4. Global Epileptic Seizures Treatment by: Seizures (Value)
          • 5.2.4.1. Generalized Seizures
          • 5.2.4.2. Whole Brain
      • 5.3. Global Epileptic Seizures Treatment (Volume)
        • 5.3.1. Global Epileptic Seizures Treatment by: Type (Volume)
          • 5.3.1.1. Convulsive Status Epilepticus
          • 5.3.1.2. Non-Convulsive Status Epilepticus
        • 5.3.2. Global Epileptic Seizures Treatment by: Distribution Channel (Volume)
          • 5.3.2.1. Online
          • 5.3.2.2. Offline
        • 5.3.3. Global Epileptic Seizures Treatment by: Route Of Administration (Volume)
          • 5.3.3.1. Oral
          • 5.3.3.2. Rectal
          • 5.3.3.3. Nasal
          • 5.3.3.4. Parenteral
        • 5.3.4. Global Epileptic Seizures Treatment by: Seizures (Volume)
          • 5.3.4.1. Generalized Seizures
          • 5.3.4.2. Whole Brain
      • 5.4. Global Epileptic Seizures Treatment (Price)
        • 5.4.1. Global Epileptic Seizures Treatment by: Type (Price)
    • 6. Epileptic Seizures Treatment: Manufacturers/Players Analysis
      • 6.1. Competitive Landscape
        • 6.1.1. Market Share Analysis
          • 6.1.1.1. Top 3
          • 6.1.1.2. Top 5
      • 6.2. Peer Group Analysis (2019)
      • 6.3. BCG Matrix
      • 6.4. Company Profile
        • 6.4.1. Bausch Health Companies, Inc. (Canada)
          • 6.4.1.1. Business Overview
          • 6.4.1.2. Products/Services Offerings
          • 6.4.1.3. Financial Analysis
          • 6.4.1.4. SWOT Analysis
        • 6.4.2. GlaxoSmithKline plc. (United Kingdom)
          • 6.4.2.1. Business Overview
          • 6.4.2.2. Products/Services Offerings
          • 6.4.2.3. Financial Analysis
          • 6.4.2.4. SWOT Analysis
        • 6.4.3. UCB S.A. (Belgium)
          • 6.4.3.1. Business Overview
          • 6.4.3.2. Products/Services Offerings
          • 6.4.3.3. Financial Analysis
          • 6.4.3.4. SWOT Analysis
        • 6.4.4. Pfizer, Inc. (United States)
          • 6.4.4.1. Business Overview
          • 6.4.4.2. Products/Services Offerings
          • 6.4.4.3. Financial Analysis
          • 6.4.4.4. SWOT Analysis
        • 6.4.5. Apotex, Inc. (Canada)
          • 6.4.5.1. Business Overview
          • 6.4.5.2. Products/Services Offerings
          • 6.4.5.3. Financial Analysis
          • 6.4.5.4. SWOT Analysis
        • 6.4.6. Alexza Pharmaceuticals, Inc. (United States)
          • 6.4.6.1. Business Overview
          • 6.4.6.2. Products/Services Offerings
          • 6.4.6.3. Financial Analysis
          • 6.4.6.4. SWOT Analysis
        • 6.4.7. Neurelis, Inc. (United States)
          • 6.4.7.1. Business Overview
          • 6.4.7.2. Products/Services Offerings
          • 6.4.7.3. Financial Analysis
          • 6.4.7.4. SWOT Analysis
        • 6.4.8. Veriton Pharma (United Kingdom)
          • 6.4.8.1. Business Overview
          • 6.4.8.2. Products/Services Offerings
          • 6.4.8.3. Financial Analysis
          • 6.4.8.4. SWOT Analysis
    • 7. Global Epileptic Seizures Treatment Sale, by Type, Therapeutic , Distribution Channel, Route Of Administration and Seizures (value, volume and price ) (2020-2025)
      • 7.1. Introduction
      • 7.2. Global Epileptic Seizures Treatment (Value)
        • 7.2.1. Global Epileptic Seizures Treatment by: Type (Value)
          • 7.2.1.1. Convulsive Status Epilepticus
          • 7.2.1.2. Non-Convulsive Status Epilepticus
        • 7.2.2. Global Epileptic Seizures Treatment by: Distribution Channel (Value)
          • 7.2.2.1. Online
          • 7.2.2.2. Offline
        • 7.2.3. Global Epileptic Seizures Treatment by: Route Of Administration (Value)
          • 7.2.3.1. Oral
          • 7.2.3.2. Rectal
          • 7.2.3.3. Nasal
          • 7.2.3.4. Parenteral
        • 7.2.4. Global Epileptic Seizures Treatment by: Seizures (Value)
          • 7.2.4.1. Generalized Seizures
          • 7.2.4.2. Whole Brain
      • 7.3. Global Epileptic Seizures Treatment (Volume)
        • 7.3.1. Global Epileptic Seizures Treatment by: Type (Volume)
          • 7.3.1.1. Convulsive Status Epilepticus
          • 7.3.1.2. Non-Convulsive Status Epilepticus
        • 7.3.2. Global Epileptic Seizures Treatment by: Distribution Channel (Volume)
          • 7.3.2.1. Online
          • 7.3.2.2. Offline
        • 7.3.3. Global Epileptic Seizures Treatment by: Route Of Administration (Volume)
          • 7.3.3.1. Oral
          • 7.3.3.2. Rectal
          • 7.3.3.3. Nasal
          • 7.3.3.4. Parenteral
        • 7.3.4. Global Epileptic Seizures Treatment by: Seizures (Volume)
          • 7.3.4.1. Generalized Seizures
          • 7.3.4.2. Whole Brain
      • 7.4. Global Epileptic Seizures Treatment (Price)
        • 7.4.1. Global Epileptic Seizures Treatment by: Type (Price)
    • 8. Appendix
      • 8.1. Acronyms
    • 9. Methodology and Data Source
      • 9.1. Methodology/Research Approach
        • 9.1.1. Research Programs/Design
        • 9.1.2. Market Size Estimation
        • 9.1.3. Market Breakdown and Data Triangulation
      • 9.2. Data Source
        • 9.2.1. Secondary Sources
        • 9.2.2. Primary Sources
      • 9.3. Disclaimer
    List of Tables
    • Table 1. Epileptic Seizures Treatment: by Type(USD Million)
    • Table 2. Epileptic Seizures Treatment: by Distribution Channel(USD Million)
    • Table 3. Epileptic Seizures Treatment: by Route Of Administration(USD Million)
    • Table 4. Epileptic Seizures Treatment: by Seizures(USD Million)
    • Table 5. Epileptic Seizures Treatment Sales: by Type(K Units)
    • Table 6. Epileptic Seizures Treatment Sales: by Distribution Channel(K Units)
    • Table 7. Epileptic Seizures Treatment Sales: by Route Of Administration(K Units)
    • Table 8. Epileptic Seizures Treatment Sales: by Seizures(K Units)
    • Table 9. Epileptic Seizures Treatment: by Type(USD/Units)
    • Table 10. Company Basic Information, Sales Area and Its Competitors
    • Table 11. Company Basic Information, Sales Area and Its Competitors
    • Table 12. Company Basic Information, Sales Area and Its Competitors
    • Table 13. Company Basic Information, Sales Area and Its Competitors
    • Table 14. Company Basic Information, Sales Area and Its Competitors
    • Table 15. Company Basic Information, Sales Area and Its Competitors
    • Table 16. Company Basic Information, Sales Area and Its Competitors
    • Table 17. Company Basic Information, Sales Area and Its Competitors
    • Table 18. Epileptic Seizures Treatment: by Type(USD Million)
    • Table 19. Epileptic Seizures Treatment: by Distribution Channel(USD Million)
    • Table 20. Epileptic Seizures Treatment: by Route Of Administration(USD Million)
    • Table 21. Epileptic Seizures Treatment: by Seizures(USD Million)
    • Table 22. Epileptic Seizures Treatment Sales: by Type(K Units)
    • Table 23. Epileptic Seizures Treatment Sales: by Distribution Channel(K Units)
    • Table 24. Epileptic Seizures Treatment Sales: by Route Of Administration(K Units)
    • Table 25. Epileptic Seizures Treatment Sales: by Seizures(K Units)
    • Table 26. Epileptic Seizures Treatment: by Type(USD/Units)
    • Table 27. Research Programs/Design for This Report
    • Table 28. Key Data Information from Secondary Sources
    • Table 29. Key Data Information from Primary Sources
    List of Figures
    • Figure 1. Porters Five Forces
    • Figure 2. Supply/Value Chain
    • Figure 3. PESTEL analysis
    • Figure 4. Global Epileptic Seizures Treatment: by Type USD Million (2014-2019)
    • Figure 5. Global Epileptic Seizures Treatment: by Distribution Channel USD Million (2014-2019)
    • Figure 6. Global Epileptic Seizures Treatment: by Route Of Administration USD Million (2014-2019)
    • Figure 7. Global Epileptic Seizures Treatment: by Seizures USD Million (2014-2019)
    • Figure 8. Global Epileptic Seizures Treatment: by Type K Units (2014-2019)
    • Figure 9. Global Epileptic Seizures Treatment: by Distribution Channel K Units (2014-2019)
    • Figure 10. Global Epileptic Seizures Treatment: by Route Of Administration K Units (2014-2019)
    • Figure 11. Global Epileptic Seizures Treatment: by Seizures K Units (2014-2019)
    • Figure 12. Global Epileptic Seizures Treatment: by Type USD/Units (2014-2019)
    • Figure 13. Global Epileptic Seizures Treatment share by Players 2019 (%)
    • Figure 14. Global Epileptic Seizures Treatment share by Players (Top 3) 2019(%)
    • Figure 15. Global Epileptic Seizures Treatment share by Players (Top 5) 2019(%)
    • Figure 16. BCG Matrix for key Companies
    • Figure 17. Bausch Health Companies, Inc. (Canada) Revenue, Net Income and Gross profit
    • Figure 18. Bausch Health Companies, Inc. (Canada) Revenue: by Geography 2019
    • Figure 19. GlaxoSmithKline plc. (United Kingdom) Revenue, Net Income and Gross profit
    • Figure 20. GlaxoSmithKline plc. (United Kingdom) Revenue: by Geography 2019
    • Figure 21. UCB S.A. (Belgium) Revenue, Net Income and Gross profit
    • Figure 22. UCB S.A. (Belgium) Revenue: by Geography 2019
    • Figure 23. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
    • Figure 24. Pfizer, Inc. (United States) Revenue: by Geography 2019
    • Figure 25. Apotex, Inc. (Canada) Revenue, Net Income and Gross profit
    • Figure 26. Apotex, Inc. (Canada) Revenue: by Geography 2019
    • Figure 27. Alexza Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
    • Figure 28. Alexza Pharmaceuticals, Inc. (United States) Revenue: by Geography 2019
    • Figure 29. Neurelis, Inc. (United States) Revenue, Net Income and Gross profit
    • Figure 30. Neurelis, Inc. (United States) Revenue: by Geography 2019
    • Figure 31. Veriton Pharma (United Kingdom) Revenue, Net Income and Gross profit
    • Figure 32. Veriton Pharma (United Kingdom) Revenue: by Geography 2019
    • Figure 33. Global Epileptic Seizures Treatment: by Type USD Million (2020-2025)
    • Figure 34. Global Epileptic Seizures Treatment: by Distribution Channel USD Million (2020-2025)
    • Figure 35. Global Epileptic Seizures Treatment: by Route Of Administration USD Million (2020-2025)
    • Figure 36. Global Epileptic Seizures Treatment: by Seizures USD Million (2020-2025)
    • Figure 37. Global Epileptic Seizures Treatment: by Type K Units (2020-2025)
    • Figure 38. Global Epileptic Seizures Treatment: by Distribution Channel K Units (2020-2025)
    • Figure 39. Global Epileptic Seizures Treatment: by Route Of Administration K Units (2020-2025)
    • Figure 40. Global Epileptic Seizures Treatment: by Seizures K Units (2020-2025)
    • Figure 41. Global Epileptic Seizures Treatment: by Type USD/Units (2020-2025)
    Some of the key companies/manufacturers profiled in the report
    • Bausch Health Companies, Inc. (Canada)
    • GlaxoSmithKline plc. (United Kingdom)
    • UCB S.A. (Belgium)
    • Pfizer, Inc. (United States)
    • Apotex, Inc. (Canada)
    • Alexza Pharmaceuticals, Inc. (United States)
    • Neurelis, Inc. (United States)
    • Veriton Pharma (United Kingdom)
    Select License Type
    Sample Report Enquiry Before Buy Request Discount

    Speak with Analyst

    Want to find out more about this report?

    Get Free Consultation